Journal Information
Most cited
79
STAT3: A key regulator in liver fibrosisJie Zhao, Yong-Fen Qi, Yan-Rong Yu
Ann Hepatol. 2021;21C:224
79
Open access
75
Liver disease and outcomes among COVID-19 hospitalized patients – A systematic review and meta-analysisAshish Sharma, Pragya Jaiswal, Yasameen Kerakhan, Lakshmi Saravanan, Zeba Murtaza, Azka Zergham, Nagaraj-Sanchitha Honganur, Aelia Akbar, ... Preeti Malik
Ann Hepatol. 2021;21C:273
75
Open access
Open Article
54
Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma." Review articleMohamad Mouchli, Shravani Reddy, Miranda Gerrard, Lisa Boardman, Marrieth Rubio
Ann Hepatol. 2021;22C:249
54
Open access
47
The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studiesUmar Hayat, Ali A. Siddiqui, Hayrettin Okut, Saba Afroz, Syed Tasleem, Ahmed Haris
Ann Hepatol. 2021;20C:254
47
Open access
41
Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19)Ivan Lopez-Mendez, Jorge Aquino-Matus, Sofia Murua-Beltrán Gall, Jose D. Prieto-Nava, Eva Juarez-Hernandez, Misael Uribe, Graciela Castro-Narro
Ann Hepatol. 2021;20C:271
41
Open access
Open Article
31
Standardization of conventional chemoembolization for hepatocellular carcinomaMatteo Renzulli, Giuliano Peta, Francesco Vasuri, Giovanni Marasco, Daniele Caretti, Laura Bartalena, Daniele Spinelli, Emanuela Giampalma, ... Rita Golfieri
Ann Hepatol. 2021;22C:278
31
Open access
31
Clinical features and risk factors of COVID-19-associated liver injury and function: A retrospective analysis of 830 casesFaxiang Chen, Wei Chen, Jianpu Chen, Dan Xu, Wei Xie, Xiang Wang, Yuanliang Xie
Ann Hepatol. 2021;21C:267
31
Open access
Open Article
31
Silymarin is an ally against insulin resistance: A reviewKarla MacDonald-Ramos, Layla Michán, Alejandra Martínez-Ibarra, Marco Cerbón
Ann Hepatol. 2021;23C:255
31
Open access
28
Prospective Latin American cohort evaluating outcomes of patients with COVID-19 and abnormal liver tests on admissionManuel Mendizabal, Federico Piñero, Ezequiel Ridruejo, Margarita Anders, María Dolores Silveyra, Aldo Torre, Pedro Montes, Alvaro Urzúa, ... Marcelo O Silva
Ann Hepatol. 2021;21C:100298
28
Open access
Open Article
25
Non-alcoholic fatty liver disease and microRNAs expression, how it affects the development and progression of the diseaseGuillermo Nahúm López-Sánchez, Mayra Dóminguez-Pérez, Misael Uribe, Norberto Carlos Chávez-Tapia, Natalia Nuño-Lámbarri
Ann Hepatol. 2021;21C:212
25
Open access